{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T07:45:15Z","timestamp":1776584715506,"version":"3.51.2"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["701596"],"award-info":[{"award-number":["701596"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctro.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T14:38:25Z","timestamp":1665671905000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial"],"prefix":"10.1016","volume":"37","author":[{"given":"Anand","family":"Swaminath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Wierzbicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Parpia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayananda","family":"Kundapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naseer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Bujold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Hirmiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ramchandar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Filion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Yaremko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Gabos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Mehiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros K.","family":"Tsakiridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Cline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2022.10.002_b0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2011.05.073","article-title":"Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting","volume":"100","author":"Weber","year":"2011","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2022.10.002_b0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2020.06.002","article-title":"Urethra-sparing stereotactic body radiation therapy for prostate cancer: quality assurance of a randomized phase 2 trial","volume":"108","author":"Jaccard","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ijrobp.2018.04.015","article-title":"Radiation Therapy Quality Assurance (RTQA) of concurrent chemoradiation therapy for locally advanced non-small cell lung cancer in the PROCLAIM phase 3 trial","volume":"101","author":"Brade","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0020","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijrobp.2013.03.036","article-title":"Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review","volume":"87","author":"Fairchild","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0025","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctro.2022.10.002_b0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.radonc.2021.11.018","article-title":"The radiotherapy quality assurance gap among phase III cancer clinical trials","volume":"166","author":"Corrigan","year":"2021","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2022.10.002_b0035","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cllc.2016.08.002","volume":"18","author":"Swaminath","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctro.2022.10.002_b0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0045","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","article-title":"Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus","volume":"81","author":"Kong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0050","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.ijrobp.2005.05.034","article-title":"Clinical outcomes of a phase I\/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame","volume":"63","author":"Nagata","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0055","first-page":"S115","article-title":"A Japan clinical oncology group trial for stereotactic body radiation therapy of non-small cell lung cancer","volume":"2","author":"Hiraoka","year":"2007","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctro.2022.10.002_b0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2018.10.025","article-title":"Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results","volume":"132","author":"Lambrecht","year":"2019","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2022.10.002_b0065","doi-asserted-by":"crossref","first-page":"20170737","DOI":"10.1259\/bjr.20170737","article-title":"Credentialing of radiotherapy centres in Australasia for TROG 09.02 (Chisel), a Phase III clinical trial on stereotactic ablative body radiotherapy of early stage lung cancer","volume":"91","author":"Kron","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctro.2022.10.002_b0070","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijrobp.2006.12.012","article-title":"Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer","volume":"68","author":"Matsuo","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0075","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ijrobp.2015.08.029","article-title":"Optimizing radiation therapy quality assurance in clinical trials: A TROG 08.03 RAVES substudy","volume":"93","author":"Trada","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0080","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2019.06.2542","article-title":"Quality assurance of dose-escalated radiation therapy in a randomized trial for locally advanced oesophageal cancer","volume":"105","author":"Boustani","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.002_b0085","first-page":"527","article-title":"The impact of peer review of volume delineation in stereotactic body radiation therapy planning for primary lung cancer: a multicenter quality assurance study","volume":"9","author":"Lo","year":"2014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctro.2022.10.002_b0090","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.prro.2015.09.009","article-title":"Enhancing safety and quality through preplanning peer review for patients undergoing stereotactic body radiation therapy","volume":"6","author":"Matuszak","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.10.002_b0095","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/j.prro.2019.12.004","article-title":"Assessing the variability and quality of lung stereotactic radiation therapy treatment plans using a web-based crowdsourcing platform","volume":"10","author":"Moghanaki","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.10.002_b0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/09553002.2019.1552375","article-title":"Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis","volume":"95","author":"Rim","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.ctro.2022.10.002_b0105","first-page":"1081","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctro.2022.10.002_b0110","first-page":"1332","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: A systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctro.2022.10.002_b0115","first-page":"1200","article-title":"The HILUS-Trial-a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.ctro.2022.10.002_b0120","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/0284186X.2021.1942545","article-title":"Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy","volume":"60","author":"Lodeweges","year":"2021","journal-title":"Acta Oncol Stockh Swed"},{"key":"10.1016\/j.ctro.2022.10.002_b0125","doi-asserted-by":"crossref","first-page":"100750","DOI":"10.1016\/j.adro.2021.100750","article-title":"Evidence-Based Planning Target Volume Margin Reduction for Modern Lung Stereotactic Ablative Radiation Therapy Using Deformable Registration","volume":"6","author":"Jasper","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.10.002_b0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejmp.2017.04.003","article-title":"The role of dosimetry audit in lung SBRT multi-centre clinical trials","volume":"44","author":"Clark","year":"2017","journal-title":"Phys Med"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:10:07Z","timestamp":1762503007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630822000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":26,"alternative-id":["S2405630822000866"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.10.002","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}